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Abstract
Background: Recombinant granulocyte colony-stimulating factors (G-CSFs) such as Filgrastim are
used to treat chemotherapy-induced neutropenia. We investigated a new G-CSF, XM02, and
compared it to Neupogen™ after myelotoxic chemotherapy in breast cancer (BC) patients.
Methods: A total of 348 patients with BC receiving docetaxel/doxorubicin chemotherapy were
randomised to treatment with daily injections (subcutaneous 5 μg/kg/day) for at least 5 days and a
maximum of 14 days in each cycle of XM02 (n = 140), Neupogen™ (n = 136) or placebo (n = 72).
The primary endpoint was the duration of severe neutropenia (DSN) in cycle 1.
Results: The mean DSN in cycle 1 was 1.1, 1.1, and 3.9 days in the XM02, Neupogen™, and
placebo group, respectively. Superiority of XM02 over placebo and equivalence of XM02 with
Neupogen™ could be demonstrated. Toxicities were similar between XM02 and Neupogen™.
Conclusion: XM02 was superior to placebo and equivalent to Neupogen™ in reducing DSN after
myelotoxic chemotherapy.
Trial Registration: Current Controlled Trials ISRCTN02270769
Introduction
Myelotoxic chemotherapy frequently leads to neutrope-
nia. Recombinant granulocyte colony-stimulating factors
(G-CSFs) are effective pharmaceutical substances and are
successfully applied in the prevention of chemotherapy-
induced neutropenia and the associated risk of infection.
[1-3]
Natural human G-CSF is a glycoprotein composed of a
single polypeptide chain of 174 or 177 amino acids.[4,5]
The first bacterially synthesised non-glycosylated recom-
binant methionyl form of human G-CSF (r-metHuG -
CSF) was approved by the Food and Drug Administration
(FDA) in 1991 under the generic name Filgrastim. Alter-
natively, a second glycosylated recombinant human G-
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CSF is available on the market under the generic name
Lenograstim which is produced by Chinese hamster ovary
(CHO) cells.
More recently, a biosimilar non-glycosylated r-metHuG-
CSF expressed in Escherichia coli for intravenous (i.v.) and
subcutaneous (s.c.) administration was clinically devel-
oped by BioGeneriX AG for the treatment of chemother-
apy-induced neutropenia. The manufacturing process was
developed by Sicor Biotech. XM02 will be named with the
international non-proprietary name filgrastim. Filgrastim
marketed under the trade name Neupogen™ was used as
reference product in this study.
The primary aim of the study was to demonstrate the
activity of XM02 compared to Neupogen™ and placebo.
We show that XM02 is safe and well tolerated in breast
cancer patients undergoing chemotherapy and is very sim-
ilar to Neupogen™ in effectively stimulating neutrophil
recovery.
Methods
Patients
Between December 2004 and September 2005, patients
with breast cancer requiring chemotherapy participated in
this multinational, multicentre, randomised and control-
led phase III study at 52 study centres in 10 countries. The
study was approved by all local institutional review
boards and ethics committees concerned. The first ethics
committee approval was given by the National Ethics
Committee of Medicamentului Student Clinic, Bucharest,
subsequently followed by the approvals for all 52 centres
involved. Male and female patients ≥ 18 years of age with
breast cancer high risk stage II, III or IV (classification
according to American Joint Committee on Cancer) were
eligible to participate if they signed written informed con-
sent, were planned/eligible to receive treatment with
docetaxel/doxorubicin as routine chemotherapy for their
breast cancer, were chemotherapy-naïve, had Eastern
Cooperative Oncology Group performance status ≤ 2, an
absolute neutrophil count (ANC) ≥ 1.5 × 109/L, platelet
count ≥ 100 × 109/L, adequate cardiac function (including
left ventricular ejection fraction ≥ 50% as assessed by
echocardiography within 4 weeks prior to randomisa-
tion), adequate hepatic function, i.e., alanine and aspar-
tate aminotransferases <2.5 × upper limit of normal
(ULN), alkaline phosphatase <5 × ULN, bilirubin <ULN,
and adequate renal function, i.e., creatinine <1.5 × ULN.
Methods
A total of 348 patients were randomised in a 2:2:1 ratio to
treatment with either XM02 (n = 140), Neupogen™ (n =
136) or placebo (n = 72). Patients in the placebo group
switched to treatment with XM02 after completion of
cycle 1. Patients underwent a maximum of 4 chemother-
apy cycles (3 weeks per cycle), consisting of doxorubicin
60 mg/m2 (i.v. bolus injection) and docetaxel 75 mg/m2
(at least 1 hour infusion). Starting one day after chemo-
therapy, patients received daily injections of either XM02
or Neupogen™ (both s.c. 5 μg/kg/day based on actual
body weight) or s.c. placebo (in the first cycle only) for at
least 5 days and a maximum of 14 days. The dose of XM02
was chosen based on bioequivalence between XM02 and
Neupogen™ previously demonstrated in healthy volun-
teers [6]. Both used G-CSF had to be stopped when an
ANC of ≥ 10 × 109/L after nadir was reached. Blood sam-
ples for the determination of the ANC were taken within
24 hours before chemotherapy and then daily from Day 2
until Day 15, or longer until ANC reached ≥ 2.0 × 109/L.
Body temperature (axillary) was measured with a stand-
ardised device daily until Day 15, or longer until ANC
reached ≥ 2.0 × 109/L.
A true double-blind design was not feasible because XM02
and Neupogen™ were formulated in different volumes.
For this reason, the study drug was administered by qual-
ified unblinded study personnel and the investigator was
kept blinded and performed all assessments of the patient
without knowledge of treatment. Moreover, it was consid-
ered that the efficacy endpoints of this study (based on
ANC) were very unlikely to be influenced by the investiga-
tor's or patient's knowledge of the treatment. During cycle
1, safety was closely monitored by an independent,
unblinded Safety Monitoring Board in order to ensure
that patients in the placebo arm were not exposed to an
unjustifiable risk.
Endpoints and definitions
The primary endpoint was the duration of severe neutro-
penia (DSN) in cycle 1, defined as the number of days
with grade 4 neutropenia with an ANC <0.5 × 109/L. Sec-
ondary endpoints included incidence of observed febrile
neutropenia (FN) (observed FN defined as body tempera-
ture of >38.5°C for more than 1 hour and ANC <0.5 ×
109/L, both measured on the same day) and of protocol
defined FN (administration of systemic antibiotics) by
cycle and across all cycles, DSN in cycles 2 to 4, depth of
ANC nadir in cycles 1 to 4, and time to ANC recovery in
cycles 1 to 4. Safety assessments were based on adverse
events (AEs), safety laboratory at the beginning of each
cycle and at the end of study, immunogenicity samples
before treatment, after the end of each cycle and 180 days
after the start of treatment, physical examinations, and
vital signs. In a subgroup of patients per treatment group
pharmacokinetic samples were taken in cycle 1 and cycle
4 on day 1 and after repeated dosing on the day after the
ANC had reached 2 × 109/L. Serum concentrations were
determined with the enzyme-linked immunosorbent
assay test (ELISA) kit (Quantikine®, R&D Systems, USA)
by Cirion Biopharma Research Inc., Canada.BMC Cancer 2008, 8:332 http://www.biomedcentral.com/1471-2407/8/332
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Statistical methods
First, assay sensitivity with respect to DSN in cycle 1 was
confirmed by comparing XM02 versus placebo. If this dif-
ference was significant (analysis of covariance [ANCOVA],
two sided p ≤ 0.05 with shorter DSN for XM02), equiva-
lence between XM02 and Neupogen™ was assessed. To
show equivalence between XM02 and Neupogen™, the 2-
sided 95% confidence interval (CI) for the difference in
DSN in cycle 1 had to lie entirely within the equivalence
range of [-1 day, +1 day]. A difference of 1 day was consid-
ered to be the maximum clinically acceptable difference.
Safety endpoints were summarised using descriptive sta-
tistics and the incidence of AEs was compared for XM02
versus Neupogen™ using Fisher's exact test.
Results
The treatment groups were similar with regard to demo-
graphic and baseline characteristics. There were no rele-
vant differences between treatment groups for incidence
of prior or concomitant medications. Demographic and
baseline characteristics are summarised in Table 1.
Efficacy
The patients were exposed to the study drug for a median
of 38 days (range: 1 to 55 days). Median duration within
a cycle was 9 or 10 days (range 1 to 16 days). The patients
were exposed to a mean of 15,739.6 μg (range: 540 to
29,280 μg) of active study drug (XM02 or Neupogen™).
There were no differences between the XM02 and Neupo-
gen™ groups with regard to amount of active study drug
and the duration of exposure.
Results are summarised in Table 2 for the full analysis
(FA) set.
Duration of Severe Neutropenia
In the per protocol (PP) set, mean DSN in cycle 1 was 1.1,
1.1, and 3.9 days in the XM02, Neupogen™, and placebo
group, respectively. DSN ranged from 0 to 5 days in the
XM02 and Neupogen™ groups, and from 0 to 9 days in the
placebo group. Results were similar in the FA set, i.e.,
mean DSN in cycle 1 was 1.1, 1.1, and 3.8 days in the
XM02, Neupogen™, and placebo group, respectively.
Superiority versus placebo and assay sensitivity were eval-
uated by comparing XM02 with placebo for the FA set.
The least square mean of DSN was significantly shorter in
the XM02 group (1.141 days) than in the placebo group
(3.823 days). Thus, assay sensitivity was demonstrated.
Results for the PP set were similar and confirmed superi-
ority of XM02 over placebo and assay sensitivity.
Equivalence of XM02 and Neupogen™ was assessed based
on the PP set, using the ANCOVA model to calculate a 2-
sided 95% CI for "XM02 minus Neupogen™". The least
square mean of DSN in cycle 1 was 1.119 and 1.087 days
in the XM02 and Neupogen™ group, respectively. The
95% CI for "XM02 versus Neupogen™" was [-0.262 days,
0.325 days], which was entirely included in the pre-speci-
fied equivalence range [-1, 1], thus, equivalence was con-
cluded. Results for the FA set were similar and confirmed
equivalence of XM02 and Neupogen™.
The mean DSN in cycles 2 to 4 was similar in all treatment
groups. Mean DSN was 0.7, 0.7, and 0.5 days in cycle 2,
0.6, 0.7, and 0.6 days in cycle 3, and 0.7, 0.7, and 0.6 days
in cycle 4 in the XM02, Neupogen™, and placebo/XM02
group (treated with XM02 in cycles 2 to 4), respectively.
Febrile Neutropenia
In cycle 1, the incidence of observed or protocol defined
FN was distinctly lower in the XM02 and Neupogen™
groups (12.1% and 12.5%, respectively) compared to the
placebo group (36.1%). There were no significant differ-
ences with regard to FN incidence between the XM02 and
Neupogen™ groups neither in cycle 1 nor across all cycles.
Absolute Neutrophil Count
In cycle 1 in the placebo group, mean ANC values
decreased after Day 2 and reached a nadir on Day 11,
whereas in the XM02 and Neupogen™ groups, mean val-
ues distinctly increased, reaching a maximum on Day 3,
and then decreased to a nadir on Day 7. Thereafter, mean
values in the active treatment groups distinctly increased
again, reaching a maximum on Day 11. On Day 21, mean
values returned to values as observed on Day 1 in all treat-
ment groups. In the subsequent cycles, all treatment
groups demonstrated the same trends as for XM02 and
Neupogen™ in cycle 1 (see Figure 1).
In cycle 1, the mean ANC nadir was deeper in the placebo
group (0.2 × 109/L) compared to the XM02 and Neupo-
gen™ groups (0.7 × 109/L). In cycles 2, 3, and 4, the mean
ANC nadir was not as deep as in cycle 1 and was similar
across treatment groups with a mean value of approxi-
mately 1.0 × 109/L.
In cycle 1, the median time to ANC recovery was shorter
in the XM02 and Neupogen™ groups (8.0 and 8.0 days)
compared to the placebo group (15.0 days). In cycles 2, 3,
and 4, the time to ANC recovery was similar in all treat-
ment groups with a median of 8.0 days.
Adverse events
During the course of the study, 329 (94.5%) patients
experienced a total of 3,268 AEs. Of these, 177 were con-
sidered as severe in 104 (29.9%) patients. There were 72
serious adverse events (SAEs) in 49 (14.1%) patients.
Nine patients (2.6%) discontinued the study due to an
AE, i.e., 2 (1.4%) patients in the XM02 group, 3 (2.2%) inBMC Cancer 2008, 8:332 http://www.biomedcentral.com/1471-2407/8/332
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the Neupogen™ group, and 4 (5.6%) in the placebo/
XM02 group. The AEs leading to discontinuation in these
nine patients were: sepsis, cardio-respiratory arrest,
ischaemic stroke, syncope, pulmonary infarction, ALT
increased, hyperglycaemia and myalgia, ALT and AST
increased, thrombocytopenia. There were 3 deaths during
the study treatment period (sepsis in the placebo group/
cycle 1, cardiorespiratory arrest in the placebo group/cycle
1, and ischaemic stroke in the XM02 group/cycle 1), and
1 death after the end of study visit (metastasis in brain).
All deaths were considered not related to the study drug.
The most commonly reported AEs were nausea (in 49.4%
of patients), alopecia (48.0%), and asthenia (36.5%).
Most commonly reported drug-related AEs included bone
pain (10.3%), asthenia (7.8%), myalgia (6.3%), and diar-
Table 1: Patient Characteristics
XM02
(n = 140)
Neupogen™
(n = 136)
Placebo/XM02*
(n = 72)
Gender [N (%)]
Male 1 (0.7%) 1 (0.7%) -
Female 139 (99.3%) 135 (99.3%) 72 (100.0%)
Age [years]
Mean 51.0 51.4 49.5
SD 9.7 10.7 10.3
Median 51.0 51.0 48.0
Range 25–75 28–74 28–74
Race [N (%)]
Caucasian 120 (85.7%) 118 (86.8%) 62 (86.1%)
Black 1 (0.7%) 5 (3.7%) 2 (2.8%)
Hispanic 10 (7.1%) 10 (7.4%) 6 (8.3%)
Other 9 (6.4%) 3 (2.2%) 2 (2.8%)
Body Mass Index [kg/m2]
Mean 27.77 28.20 27.42
SD 6.11 5.70 6.02
Median 27.55 26.90 27.30
Range 16.2–56.2 15.9–45.4 17.0–41.3
Cancer stage [N (%)]
High risk stage II 23 (16.4%) 36 (26.5%) 15 (20.8%)
Stage III 79 (56.4%) 69 (50.7%) 38 (52.8%)
Stage IV 38 (27.1%) 31 (22.8%) 19 (26.4%)
Therapy [N (%)]
Adjuvant 96 (68.6%) 96 (70.6%) 47 (65.3%)
Metastatic 44 (31.4%) 40 (29.4%) 25 (34.7%)
Prior radiation therapy [N (%)]
No 125 (89.3%) 127 (93.4%) 63 (87.5%)
Yes 15 (10.7%) 9 (6.6%) 9 (12.5%)
Abbreviations: SD = Standard deviation,
Body Mass Index calculated as body weight/(height)2
*Patients in this group received placebo in cycle 1 and XM02 afterwardsBMC Cancer 2008, 8:332 http://www.biomedcentral.com/1471-2407/8/332
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rhoea (5.2%). In general, drug-related AEs occurred early
in the study, i.e., they were reported within 15 days after
study start and within the first 4 days of a cycle.
The AE profile was similar between the XM02 and Neup-
ogen™ groups with exception of the incidence of drug-
related AEs across all cycles, which were seen more fre-
quently in the Neupogen™ group (in 39.7% of patients)
than in the XM02 group (25.7%) (p = 0.0149).
Patients in the placebo group in cycle 1 had a higher inci-
dence of AEs, SAEs, and severe SAEs compared to the
XM02 and Neupogen™ groups. The Safety Monitoring
Board decided to continue with the placebo group after
200 of a total of 350 planned patients had completed
cycle 1.
Immunogenicity was low in all treatment groups. Few
patients developed binding anti-G-CSF antibodies in all
treatment groups whereas no confirmed plausible neu-
tralising antibodies were detected.
Pharmacokinetics
The pharmacokinetic profiles of XM02 and Neupogen™
were similar and t1/2 values correspond to published data
on Neupogen™. In cycle 1 and cycle 4 in both profiles,
mean serum concentrations of XM02 and Neupogen™
increased, reaching a maximum at 4 to 6 hours after dos-
ing, and returned to pre-dose values by 24 hours. The
median of t1/2 was similar in the XM02 and Filgrastim
groups, i.e., 3.040 and 3.225 hours, respectively, in cycle
1 first profile, and 3.390 and 3.085 hours, respectively, in
the second profile. In cycle 4, in both profiles, the median
of t1/2 was similar in all treatment groups, ranging from
3.395 to 3.865 hours.
Discussion
The primary aim of this study was to compare XM02 with
placebo and Neupogen™ in terms of efficacy and safety in
the treatment of chemotherapy-induced neutropenia. By
testing of superiority of XM02 versus placebo, assay sensi-
tivity with respect to the primary endpoint, DSN in cycle
1, was confirmed.
In this study, mean DSN in cycle 1 was 1.1 days for
patients treated with Neupogen™ or XM02, and 3.9 days
for patients receiving placebo. In the subsequent cycles,
where all patients received XM02 or Neupogen™, mean
DSN ranged from 0.5 to 0.7 days. These are similar results
as observed in a study conducted by Holmes et al. [1],
comparing filgrastim with pegfilgrastim in breast cancer
patients, where mean DSN in the filgrastim group was 1.8
days in cycle 1, and ranged between 1.1 and 1.3 days in
the subsequent cycles. The shorter DSN observed in the
present study may be explained by the fact that only
chemotherapy-naïve patients were included.
Table 2: Results of Efficacy Endpoints
Treatment group XM02 Neupogen™ Placebo/XM02*
Full analysis set [n] (n = 140) (n = 136) 72
Mean DSN [days]
Cycle 1 1.1 1.1 3.8
ANCOVA [CI]# 0.028 [-0.261, 0.316]
Cycle 4 0.7 0.7 0.6
Mean ANC nadir [109/L]
Cycle 1 0.7 0.7 0.2
ANCOVA [CI]# -0.001 [-0.190, 0.189]
Cycle 4 1.0 1.0 1.1
Mean time to ANC recovery [days]
Cycle 1 8.0 7.8 14.0
ANCOVA [CI]# 0.207 [-0.425, 0.838]
Cycle 4 7.6 7.1 7.2
Incidence of FN [%]+
Cycle 1 12.1 12.5 36.1
Across all cycles 20.7 22.1 41.7
Abbreviations: DSN: duration of severe neutropenia; ANC: absolute neutrophil count; FN: febrile neutropenia; ANCOVA: analysis of covariance, 
CI: confidence interval.
* Patients in this group received placebo in cycle 1 and XM02 afterwards (including in cycle 4).
# ANCOVA estimate and 2-sided 95% confidence interval for difference XM02 – Filgrastim in cycle 1.
+ Observed or protocol defined FN.BMC Cancer 2008, 8:332 http://www.biomedcentral.com/1471-2407/8/332
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The incidence of observed or protocol defined FN in cycle
1 in the XM02 and Neupogen™ groups (12.1% and
12.5%, respectively) was about one third (33.5% and
34.6% respectively) compared to the placebo group
(36.1%). In a study conducted by Timmer-Bonte et al. [7],
the incidence of FN in cycle 1 during chemotherapy for
lung cancer was 10% in patients treated with antibiotics
plus G-CSF. The incidence of observed or protocol
defined FN across all cycles in our study was 20.7% and
22.1% in the XM02 and Neupogen™ groups, respectively.
Similar results were seen in the Holmes study [1], where
18% of patients in the Neupogen™ group developed FN
across all cycles. This comparison has to be interpreted
with caution as in the Holmes study [1] a different defini-
tion of FN was used. Brain et al. [8] reported an incidence
for FN of 40.8% in a breast cancer study using doxoru-
bicin 50 mg/m2/docetaxel 75 mg/m2 and suggested to use
primary G-CSF prophylaxis for this regimen. Vogel et al.
[9] showed that pegfilgrastim markedly reduced the inci-
dence of FN in breast cancer patients under moderate
myelosuppressive chemotherapy with incidences of 1%
with pegfilgrastim compared to 17% with placebo.
For patients receiving XM02 or Neupogen™, the ANC val-
ues distinctly increased after start of treatment, reaching a
maximum on Day 3, and then decreased to a nadir on Day
7. Thereafter, ANC values increased again, reaching a max-
imum on Day 11. On Day 21, mean values returned to
values as observed on Day 1. In a study conducted by
Crawford et al. in patients with lung cancer under chemo-
therapy [10], in the filgrastim group, ANC values reached
a maximum around Day 5, decreased to a nadir around
Day 10 and reached a second maximum on Day 15. Hol-
mes et al. [1] reported the same biphasic ANC profile
under treatment with filgrastim in breast cancer patients
treated with doxorubicin/docetaxel chemotherapy. In
their study, the mean time to ANC recovery was 9.7 days
for filgrastim, in our study the median time was 8.0 days
for both XM02 and Neupogen™.
In general, the safety profile of XM02 and Neupogen™ was
similar, whereas patients receiving placebo had distinctly
more AEs and SAEs. Most commonly reported drug-
related AEs were bone pain, asthenia, and myalgia, AEs
that were expected from previous studies and experience
with Neupogen™. In this study, drug-related AEs were seen
significantly more frequently in the Neupogen™ than in
the XM02 group.
In our study both G-CSF treatments were started one day
after chemotherapy according to the Summary of Product
Characteristics of Neupogen™ in order to properly com-
Mean (± SD) of Absolute Neutrophil Counts in Cycle 1 – FA Set Figure 1
Mean (± SD) of Absolute Neutrophil Counts in Cycle 1 – FA Set.
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pare both treatments. In clinical practice, G-CSF can also
be administered starting from day 5 to 6 of each cycle
[11]. This remains to be investigated in future studies with
XM02 as well. More recently, pegfilgrastim, a pegylated
form of filgrastim with a longer half life and duration of
action was introduced into the market allowing a once per
cycle administration [1].
In summary, XM02 treatment of breast cancer patients
under docetaxel/doxorubicin resulted in a significant
reduction of the DSN and the incidence of FN in cycle 1
to one third when compared to placebo. The reduction
was similar in the XM02 and Neupogen™ group.
Conclusion
In conclusion, treatment with XM02 is beneficial in amel-
iorating severe neutropenia and FN in breast cancer
patients receiving myelosuppressive chemotherapy.
XM02 is safe and well tolerated in the doses applied in this
study.
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